Advanced assay design to compensate for emerging SARS-CoV-2 mutations
In order to provide increased confidence in our COVID-19 test results as SARS-CoV-2 continues to mutate, our TaqPath COVID-19 2.0 tests employ an advanced assay design with increased target redundancy to compensate for both currently known and future SARS-CoV-2 mutations.
Blog series: The Next Generation of COVID-19 Testing
Thermo Scientific KingFisher Flex Purification System with
Applied Biosystems MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit
*LOD of 750 GCE/mL using QuantStudio 7 Flex instrument (384-well); LOD of 1,000 GCE/mL using QuantStudio 5 instrument (96-well, 0.2 mL)
TaqPath COVID-19 2.0 test menu
Thermo Fisher Scientific continues to provide gold standard testing technology with our evolved suite of PCR-based TaqPath COVID-19 2.0 tests, which were developed to help laboratories quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
Features of the TaqPath COVID-19 2.0 test menu:
Same accuracy and reliability you’ve grown to trust—An advanced assay design compensates for current and emerging mutations, helping provide continued confidence in results now and into the future
Multiple workflow options—Choose from 3 tests options: two utilize a standard workflow that includes RNA extraction, and the third utilizes a fast, direct-to-PCR workflow with no RNA extraction required
Affordable and scalable—Add to your existing COVID-19 test menu using your current real-time PCR instrumentation
Find your IFU
Find the approved Instructions for Use (IFU) for your country. (Note: Product availability varies by country.)